Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Healthy
Interventions
GE-145 (AN113111) Injection, Visipaque (iodixanol) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC), Mesothelioma
Interventions
Stereotactic Body Radiation Therapy (SBRT), Computed Tomography (CT), Cyberknife, Trilogy, True Beam, Iohexol, Iodixanol
Radiation · Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Stanford, California
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Normal eGFR

NCT01137786
Conditions
Coronary Artery Stenosis
Interventions
Non ionic contrast media comparator
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Springfield, Illinois
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Moderate Fall in eGFR

NCT01136876
Conditions
Coronary Artery Stenosis
Interventions
Iopamidol, Iodixanol-320
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Springfield, Illinois • New Brunswick, New Jersey • Teaneck, New Jersey
Conditions
Peripheral Arterial Occlusive Disease
Interventions
iopamidol, iodixanol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Chronic Renal Impairment, Diabetes Mellitus
Interventions
Iopamidol injection 76%, iodixanol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Chronic Kidney Diseases
Interventions
Visipaque, Placebos
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more
Conditions
Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
Interventions
Iodixanol, Angiogram, Arterial Embolization, Polyvinyl Alcohol, Ethiodized Oil, Computed Tomography, Chart Abstraction
Other · Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Healthy Volunteers
Interventions
NCTX (PEGylated Liposomal Iodixanol Injection), Saline Placebo
Drug
Lead sponsor
Marval Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 3 Interventional Results available

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
Drug · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey